Zabeau; Lennart
Patent Applications and Registrations
Patent applications and USPTO patent grants for Zabeau; Lennart.The latest application filed is for "chimeric proteins and chimeric protein complexes directed to fms-like tyrosine kinase 3 (flt3)".
- Zabeau; Lennart - Zwijnaarde BE
- ZABEAU; Lennart - Gent BE
- ZABEAU; Lennart - Ghent BE
| Patent | Date |
|---|---|
| Therapeutic interferon alpha 1 proteins Grant 11,440,943 - Kley , et al. September 13, 2 | 2022-09-13 |
| Chimeric Proteins And Chimeric Protein Complexes Directed To Fms-like Tyrosine Kinase 3 (flt3) App 20220177550 - KLEY; Nikolai ; et al. | 2022-06-09 |
| Clec9a-based Chimeric Protein Complexes App 20220153801 - KLEY; Nikolai ; et al. | 2022-05-19 |
| Modulation Of Dendritic Cell Lineages App 20220119472 - KLEY; Nikolai ; et al. | 2022-04-21 |
| Targeted Mutant Interferon-gamma And Uses Thereof App 20210403525 - KLEY; Nikolai ; et al. | 2021-12-30 |
| Targeted mutant interferon-gamma and uses thereof Grant 11,084,859 - Kley , et al. August 10, 2 | 2021-08-10 |
| Targeting Of Human Interferon Antagonists App 20210238247 - TAVERNIER; Jan ; et al. | 2021-08-05 |
| Targeted Engineered Interferon And Uses Thereof App 20210230291 - KLEY; Nikolai ; et al. | 2021-07-29 |
| Targeting of human interferon antagonists Grant 10,947,288 - Tavernier , et al. March 16, 2 | 2021-03-16 |
| Targeted engineered interferon and uses thereof Grant 10,906,985 - Kley , et al. February 2, 2 | 2021-02-02 |
| Bi-functional Proteins And Construction Thereof App 20210024631 - KLEY; Nikolai ; et al. | 2021-01-28 |
| Clec9a Binding Agents And Use Thereof App 20210024637 - KLEY; Nikolai ; et al. | 2021-01-28 |
| Pd-1 And Pd-l1 Binding Agents App 20200407448 - KLEY; Nikolai ; et al. | 2020-12-31 |
| Therapeutic Interferon Alpha 1 Proteins App 20200308244 - KLEY; Nikolai ; et al. | 2020-10-01 |
| Cd8 Binding Agents App 20200231674 - KLEY; Nikolai ; et al. | 2020-07-23 |
| Targeted Engineered Interferon And Uses Thereof App 20200071414 - KLEY; Nikolai ; et al. | 2020-03-05 |
| Targeted Mutant Interferon-gamma And Uses Thereof App 20200055912 - KLEY; Nikolai ; et al. | 2020-02-20 |
| Targeting Of Cytokine Antagonists App 20180334489 - TAVERNIER; Jan ; et al. | 2018-11-22 |
| Targeting Of Cytokine Antagonists App 20180334488 - TAVERNIER; Jan ; et al. | 2018-11-22 |
| Targeting of human interferon antagonists Grant 10,072,059 - Tavernier , et al. September 11, 2 | 2018-09-11 |
| Targeting Of Cytokine Antagonists App 20180057555 - Tavernier; Jan ; et al. | 2018-03-01 |
| Targeting of human interferon antagonists Grant 9,732,135 - Tavernier , et al. August 15, 2 | 2017-08-15 |
| Targeting of Cytokine Antagonists App 20160159875 - Tavemier; Jan ; et al. | 2016-06-09 |
| Methods of inhibiting leptin-induced signaling with fibronectin III domain antibodies Grant 7,575,878 - Tavernier , et al. August 18, 2 | 2009-08-18 |
| Fibronectin III Domain As Leptin Receptor Antagonists App 20070292434 - Tavernier; Jan ; et al. | 2007-12-20 |
| Functional fragment of the leptin receptor Grant 7,235,629 - Eyckerman , et al. June 26, 2 | 2007-06-26 |
| Funtional fragment of the lectine receptor App 20040116340 - Eyckerman, Sven ; et al. | 2004-06-17 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 